Innovent Biologics Signs an Expanded Agreement with Synaffix for the Development of Antibody Drug Conjugates (ADCs)
Shots:
- The expansion builds on Innovent’s Jun 2021 deal with Synaffix under which Innovent could leverage Synaffix’s ADC technologies incl. GlycoConnect, HydraSpace & one of its toxSYN linker-payloads, on a target-specific non-exclusive basis for IBI343 (a recombinant human anti- Claudin 18.2 mAb) which is currently under P-I clinical development
- As per the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing & commercialization of at least one new ADC candidate by using Synaffix’s ADC technology
- On the other hand, Synaffix is eligible to receive an up front & milestone payment of undisclosed amounts plus royalties on commercial sales for each licensed target
Ref: Innovent | Image: Innovent
Related News:- Innovent Reports First Patient Dosing of IBI343 in P-I Study for the Treatment of Advanced Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
